Breast cancer (early) - paclitaxel

Summary

Paclitaxel is not recommended as an option for the adjuvant treatment of women with early node-postive breast cancer.

Because Paclitaxel within its licensed indication is not recommended for the adjuvant treatment of women with early node-positive breast cancer then it is not considered to have any significant cost implications. Therefore, no costing template has been developed for this appraisal.

Documents

For healthcare professionals

• TA108 Breast cancer (early) paclitaxel: Quick Reference Guide
• TA108 Breast cancer (early) paclitaxel: Guidance (MS Word version)
• TA108 Breast cancer (early) paclitaxel: Guidance

For patients, carers and the public

• TA108 Breast cancer (early) paclitaxel: Understanding NICE Guidance (MS word version)
• TA108 Breast cancer (early) paclitaxel: Understanding NICE Guidance

Background information

• Review Decision - November 2007
• Review Proposal September 2007: Appendix A
• Review Proposal September 2007
• 2006/044 New NICE guidance to improve care for early breast cancer
• 2006/044 New NICE guidance to improve care for early breast cancer

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found